Safety and PK of VX-708 in healthy subjects

Phase 1, randomised, double-blind trial of VX-708 in pain (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With Clinically Meaningful Findings in Columbia Suicide Severity Rating Scale (C-SSRS) Responses and 3 more. Started Sep 2022; status: completed.